A study of comparison of PUVASOL and NBUVB in patients with vitiligo
Introduction: Vitiligo is an acquired, hypomelanotic disease, characterized by circumscribed depigmented macules. Phototherapy, which is the use of ultraviolet irradiation with or without exogenous photosensitizer is a well established treatment option. Psoralens with sunlight as the source of ultra...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Pigment International |
| Subjects: | |
| Online Access: | http://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2018;volume=5;issue=2;spage=96;epage=102;aulast=Ravishankar |
| _version_ | 1811230805507178496 |
|---|---|
| author | Vaaruni Ravishankar Santoshdev P Rathod Siddhartha Saikia Raju G Chaudhary Rekha B Solanki |
| author_facet | Vaaruni Ravishankar Santoshdev P Rathod Siddhartha Saikia Raju G Chaudhary Rekha B Solanki |
| author_sort | Vaaruni Ravishankar |
| collection | DOAJ |
| description | Introduction: Vitiligo is an acquired, hypomelanotic disease, characterized by circumscribed depigmented macules. Phototherapy, which is the use of ultraviolet irradiation with or without exogenous photosensitizer is a well established treatment option. Psoralens with sunlight as the source of ultraviolet A-rays is known as PUVASOL. Narrow band Ultraviolet B phototherapy (NBUVB; 311–313 nm) has been introduced over the past decade. Aims: To study the clinical effectiveness and assess the safety of NBUVB and PUVASOL therapy in Vitiligo patients. Methods: The patients were randomly allocated in to two groups containing 25 patients each. Group A patients received NBUVB with an initial dose of 250 mJ/cm2, incremented by 20% with each subsequent visit till optimum dose was achieved, twice a week on non-consecutive days. Group B patients received PUVASOL-oral Trimethylpsoralen or topical 0.2% w/w Trioxsalen followed by exposure to sunlight, twice a week on non-consecutive days. The extent of repigmentation was documented at regular intervals upto 6 months. Results: Amongst patients receiving NBUVB and PUVASOL, 56% and 48% had ≥50% repigmentation respectively. Disease was unstable in 48% and 36% of patients prior to commencement of therapy which reduced to 12% and 16% after therapy, respectively. 16% and 36% of the patients experienced side effects and 76% and 48% showed excellent colour match of the repigmented patches respectively. Conclusion: While both PUVASOL and NBUVB are both good therapeutic options; NBUVB therapy is found to be more effective and more cosmetically acceptable, with better colour matching of lesions and minimal adverse effects. |
| first_indexed | 2024-04-12T10:35:09Z |
| format | Article |
| id | doaj.art-c95fcafe4fc045b893fb93dc907684d8 |
| institution | Directory Open Access Journal |
| issn | 2349-5847 2349-5782 |
| language | English |
| last_indexed | 2024-04-12T10:35:09Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Pigment International |
| spelling | doaj.art-c95fcafe4fc045b893fb93dc907684d82022-12-22T03:36:45ZengWolters Kluwer Medknow PublicationsPigment International2349-58472349-57822018-01-01529610210.4103/Pigmentinternational.Pigmentinternational_39_17A study of comparison of PUVASOL and NBUVB in patients with vitiligoVaaruni RavishankarSantoshdev P RathodSiddhartha SaikiaRaju G ChaudharyRekha B SolankiIntroduction: Vitiligo is an acquired, hypomelanotic disease, characterized by circumscribed depigmented macules. Phototherapy, which is the use of ultraviolet irradiation with or without exogenous photosensitizer is a well established treatment option. Psoralens with sunlight as the source of ultraviolet A-rays is known as PUVASOL. Narrow band Ultraviolet B phototherapy (NBUVB; 311–313 nm) has been introduced over the past decade. Aims: To study the clinical effectiveness and assess the safety of NBUVB and PUVASOL therapy in Vitiligo patients. Methods: The patients were randomly allocated in to two groups containing 25 patients each. Group A patients received NBUVB with an initial dose of 250 mJ/cm2, incremented by 20% with each subsequent visit till optimum dose was achieved, twice a week on non-consecutive days. Group B patients received PUVASOL-oral Trimethylpsoralen or topical 0.2% w/w Trioxsalen followed by exposure to sunlight, twice a week on non-consecutive days. The extent of repigmentation was documented at regular intervals upto 6 months. Results: Amongst patients receiving NBUVB and PUVASOL, 56% and 48% had ≥50% repigmentation respectively. Disease was unstable in 48% and 36% of patients prior to commencement of therapy which reduced to 12% and 16% after therapy, respectively. 16% and 36% of the patients experienced side effects and 76% and 48% showed excellent colour match of the repigmented patches respectively. Conclusion: While both PUVASOL and NBUVB are both good therapeutic options; NBUVB therapy is found to be more effective and more cosmetically acceptable, with better colour matching of lesions and minimal adverse effects.http://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2018;volume=5;issue=2;spage=96;epage=102;aulast=RavishankarNBUVBphototherapypsoralenPUVASOLvitiligo |
| spellingShingle | Vaaruni Ravishankar Santoshdev P Rathod Siddhartha Saikia Raju G Chaudhary Rekha B Solanki A study of comparison of PUVASOL and NBUVB in patients with vitiligo Pigment International NBUVB phototherapy psoralen PUVASOL vitiligo |
| title | A study of comparison of PUVASOL and NBUVB in patients with vitiligo |
| title_full | A study of comparison of PUVASOL and NBUVB in patients with vitiligo |
| title_fullStr | A study of comparison of PUVASOL and NBUVB in patients with vitiligo |
| title_full_unstemmed | A study of comparison of PUVASOL and NBUVB in patients with vitiligo |
| title_short | A study of comparison of PUVASOL and NBUVB in patients with vitiligo |
| title_sort | study of comparison of puvasol and nbuvb in patients with vitiligo |
| topic | NBUVB phototherapy psoralen PUVASOL vitiligo |
| url | http://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2018;volume=5;issue=2;spage=96;epage=102;aulast=Ravishankar |
| work_keys_str_mv | AT vaaruniravishankar astudyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT santoshdevprathod astudyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT siddharthasaikia astudyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT rajugchaudhary astudyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT rekhabsolanki astudyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT vaaruniravishankar studyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT santoshdevprathod studyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT siddharthasaikia studyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT rajugchaudhary studyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo AT rekhabsolanki studyofcomparisonofpuvasolandnbuvbinpatientswithvitiligo |